KRAS and acute myeloid leukemia: Additionally, a subset of these AML cases presents with activating mutations in the RAS GTPase family member (NRAS or KRAS) or other signaling pathway proteins, such as PTPN11 and NF1, contributing to RAS signaling dysregulation and promoting AML cell proliferation.